SCHEMBL5582573

SCHEMBL5582573

CC1=C(CN2CCN(C)CC2)CCc2cc(NC(=O)N3CCC(c4ccc(Cl)cc4)CC3)ccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 5/20 0.50
HTR2C P28335 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.45
NLRP3 Q96P20 1/20 0.45
TP53 P04637 3/20 0.44
MAPT P10636 3/20 0.44
LMNA P02545 2/20 0.44
NPC1 O15118 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43
NAMPT P43490 2/20 0.43
BID P55957 3/20 0.42
BCL2A1 Q16548 3/20 0.42
ALOX5 P09917 1/20 0.41
CHRM4 P08173 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5582880 0.93 MCHR1 (0.51) MCHR1HTR2CSMN1; SMN2TP53MAPT
SCHEMBL5582565 0.90 MCHR1 (0.53) MCHR1SMN1; SMN2TP53MAPTDRD2
SCHEMBL5582668 0.87 MCHR1 (0.59) MCHR1HTR2CSMN1; SMN2TP53MAPT
SCHEMBL5583037 0.85 MCHR1 (0.57) MCHR1HTR2CSMN1; SMN2TP53MAPT
SCHEMBL5582567 0.84 MCHR1 (0.59) MCHR1HTR2CSMN1; SMN2TP53MAPT
SCHEMBL5582717 0.82 MCHR1 (0.66) MCHR1HTR2CSMN1; SMN2NLRP3TP53
SCHEMBL5582598 0.80 MCHR1 (0.66) MCHR1HTR2CBIDBCL2A1
SCHEMBL5583052 0.77 MCHR1 (0.56) MCHR1HTR2CBIDBCL2A1
SCHEMBL5582876 0.76 MCHR1 (0.57) MCHR1HTR2CSMN1; SMN2TP53MAPT
SCHEMBL5582579 0.74 MCHR1 (0.65) MCHR1HTR2CSMN1; SMN2TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115750-B1 Melanin concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-10-03 US claimed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-7115750-B1 Melanin concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173498-A1 Melanin concentrating hormone antagonist MC1R, MCHR1, MCHR2 MCHR1 2/4885HTR2C 195/4885SMN1; SMN2 3652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.